Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 886-891

  Lee, J ^a   Lim, T ^a   Uhm, J E ^a   Park, K W ^b   Park, S H ^c   Lee, S C ^a   Park, J O ^a   Park, Y S ^a   Lim, H Y ^a   Sohn, T S ^a   Noh, J H ^a   Heo, J S ^a   Park, C K ^a   Kim, S ^a   Kang, W K ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dankook University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Chemotherapy; Prognosic factor

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH ADENOCARCINOMA; SURVIVAL TIME;

EID: 34447294245     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl501     Document Type: Article

References (30)

1. Cunningham D, Jost LM, Purkalne G, Oliveira J. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 2005; 16 (Suppl 1): 122-23
2. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol 2005; 3: 118-124.
3. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 (Suppl 3): 49-58.
4. Wanebo HJ, Kennedy BJ, Chmiel J et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218: 583-592.
5. Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. 'Real' 5-year survival rates and mortality rates in a country with high incidence. Dig Surg 1998; 15: 317-322.
6. Yoo CH, Noh SH, Shin DW et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242.
7. Kim S, Lim DH Lee J et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
8. D'Angelica M, Gonen M, Brennan MF et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
10. Cheng SH, Horng CF, Clarke JL et al. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. Int J Radiat Oncol Biol Phys 2006; 64: 1401-1409.
11. Weigelt B, Peterse JL, van 't Veer LJ, Breast cancer metastasis: Markers and models. Nat Rev Cancer 2005; 5: 591-602.
12. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534.
13. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
14. Chau I, Norman AR, Cunningham D et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395-2403.
15. Zisman A, Pantuck AJ, Dorey F et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002; 20: 1368-1374.
16. Yoshida M, Ohtsu A, Boku N et al. Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004; 34: 654-659.
17. Costa ML, de Cassia Braga Ribeiro K, Machado MA et al. Prognostic score in gastric cancer: The importance of a conjoint analysis of clinical, pathologic, and therapeutic factors. Ann Surg Oncol 2006; 13: 843-850.
18. Zhang XF, Huang CM, Lu HS et al. Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol 2004; 10: 3405-3408.
19. Kologlu M, Kama NA, Reis E et al. A prognostic score for gastric cancer. Am J Surg 2000; 179: 521-526.
20. Marrelli D, De Stefano A, de Manzoni G et al. Prediction of recurrence after radical surgery for gastric cancer: A scoring system obtained from a prospective multicenter study. Ann Surg 2005; 241: 247-255.
21. Ichikawa W, Sasaki Y. Correlation between tumor response to first line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 2006; 17: 1665-1672.
22. Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg 2006; 30: 21-27.
23. Fujisaki S, Tomita R, Nezu T et al. Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 2001; 48: 892-894.
24. Tsujitani S, Oka S, Suzuki K et al. Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: A multivariate analysis. Hepatogastroenterology 2001; 48: 1504-1508.
25. Bonenkamp JJ, Sasako M, Hermans J, van de Velde CJ. Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001; 48: 1219-1221.
26. Ryoo B KJ, Park Y, Kim B et al. Prognostic factors in patients with metastatic gastric cancer treated with cisplatin-containing chemotherapy. Gastrointest Cancers Symp 2005; Abrst 59.
27. Kobayashi M, Okabayashi T, Sano T, Araki K. Metastatic bone cancer as a recurrence of early gastric cancer - characteristics and possible mechanisms. World J Gastroenterol 2005; 11: 5587-5591.
28. Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J Surg 1983; 13: 173-176
29. Kohne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
30. Jaquet JSP. Peritoneal-plasma barrier. In Sugarbaker PhH (ed): Peritoneal Carcinomatosis: Principles of Management. Boston, MA: Kluwer 1996.